PLK4 and cancer: The treatment of transformed cancer cell lines with the PLK4 inhibitor Centrinone B to decrease inherent CA and reverse CA-induced phenotypes has previously been demonstrated (Denu et al., 2020, 2018; Wong et al., 2015).